Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CCR9 | P51686 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857106 | 0.88 | IDO1 (0.45) | IDO1ALDH1A1CA12CA9CA14 | |
| SCHEMBL13055884 | 0.85 | IDO1 (0.57) | IDO1ALDH1A1LMNACA12CA9 | |
| SCHEMBL22922181 | 0.84 | CYP4F2 (0.59) | IDO1ALDH1A1LMNACA12CA9 | |
| SCHEMBL2303459 | 0.83 | CA2 (0.65) | IDO1ALDH1A1LMNACA12CA9 | |
| SCHEMBL30898772 | 0.83 | IDO1 (0.56) | IDO1ALDH1A1LMNACA12CA9 | |
| SCHEMBL184666 | 0.83 | CYP4F2 (0.56) | ALDH1A1LMNACA12CA9CA14 | |
| SCHEMBL8066339 | 0.83 | CA2 (0.43) | IDO1ALDH1A1LMNACYP4F2CYP4A11 | |
| SCHEMBL833553 | 0.82 | IDO1 (0.54) | IDO1ALDH1A1LMNACCR9CA12 | |
| SCHEMBL3477633 | 0.82 | IDO1 (0.61) | IDO1ALDH1A1LMNACCR9KDM4E | |
| SCHEMBL5746476 | 0.81 | SIRT2 (0.47) | IDO1ALDH1A1LMNACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117402124-A | Aryl sulfonamide compound and anti-influenza application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-16 | — | — | CN | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORPORATION | 2022-11-17 | — | — | US | disclosed |
| EP-3802514-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2004085384-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040167113-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1439834-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003037328-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | IDO1 1356/4885ALDH1A1 2172/4885LMNA 3267/4885 |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | LUC7L2, LYPLAL1, GUSB | IDO1 3963/4885ALDH1A1 1554/4885LMNA 1478/4885 |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | IDO1 3963/4885ALDH1A1 1554/4885LMNA 1478/4885 |
| US-20040167113-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | IDO1 1288/4885ALDH1A1 2054/4885LMNA 4769/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | IDO1 663/4885ALDH1A1 1655/4885LMNA 4484/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | IDO1 1007/4885ALDH1A1 3993/4885LMNA 1407/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | IDO1 2676/4885ALDH1A1 2629/4885LMNA 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.